Bristol immunotherapy gets 6-month U.S. FDA review for melanoma

Sept 26 (Reuters) - The U.S. Food and Drug Administration has granted a six-month, priority review to Bristol-Myers Squibb Co's application for immuno-oncology drug Opdivo as a treatment for previously treated melanoma, the company said on Friday.